# US 2012/0252697 A1 · Transformed human pluripotent stem cells and associated methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252697 A1
- Document ID: US20120252697A1
- Status: Published application
- Kind: A1
- Application number: 13/393,475
- Filed: 2010-09-01
- Published: 2012-10-04
- Earliest claimed: 2009-09-01
- Assignees: McMaster University
- Inventors: Mickie Bhatia; Tamra Werbowetski-Ogilvie; Eleftherios Sachlos; Daniela Fischer Russell; Sarah Laronde; JungBok Lee; Eva Szabo; Ruth M. Risueno
- Web page: https://patentgrep.com/patent/US20120252697A1

## CPC

- C12Q 1/6897: involving reporter genes operably linked to promoters
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0695: {Stem cells; Progenitor cells; Precursor cells}
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides transformed human pluripotent stem cell (t-hPSC). t-hPSCs are not dependent on Oct4 for renewal and survival, however exhibit a sensitivity to reduced levels of the transcription factor Nanog. Also provided are methods of culturing cells for use in a cell-based screening assay comprising placing one or more transformed human pluripotent stem cells into a receptacle and culturing said stem cells in the receptacle to form a monolayer of stem cells without cell overlap. Methods of screening compounds using t-hPSCs are also described.

## Claims

### Claim 1

A transformed human pluripotent stem cell (t-hPSC) wherein the cell does not require bFGF for maintenance of an undifferentiated state.

### Claim 2 (depends on 1)

The transformed human pluripotent stem cell of claim 1, wherein:
a) the cell co-expresses FGFR1 and IGFR1,
b) the cell maintains expression of SSEA3 in the absence of bFGF, or
c) the cell requires Nanog for self-renewal and cell survival.

### Claim at position 3

-6. (canceled)

### Claim 7 (depends on 1)

The transformed human pluripotent stem cell of claim 1, wherein the cell exhibits reduced neuronal differentiation or reduced hematopoietic potential in vitro compared to a normal human pluripotent stem cell.

### Claim 8 (depends on 1)

The transformed human pluripotent stem cell of claim 1, wherein t-hPSC-derived neural precursors do not form metastasis in vivo.

### Claim at position 6

-10. (canceled)

### Claim 11 (depends on 1)

The transformed human pluripotent stem cell of claim 1, wherein the cell can be passaged as a single cell.

### Claim 12 (depends on 1)

A method of screening a compound for a biological activity comprising:
a) contacting one or more transformed human pluripotent stem cells (t-hPSCs) of claim 1 with the compound;
b) detecting an effect of the compound on the one or more t-hPSCs, wherein the effect is indicative of the biological activity of the compound.

### Claim 13 (depends on 12)

The method of claim 12, wherein the biological activity is cell differentiation activity or loss of pluripotency.

### Claim 14 (depends on 13)

The method of claim 13, wherein step b) comprises detecting the emergence of progenitor or precursor cells from the one or more t-hPSCs that are otherwise refractory to differentiation.

### Claim 15 (depends on 13)

The method of claim 13, wherein step b) comprises detecting the expression of one of more biomarkers selected from the group consisting of Oct4, Sox2, Nanog, SSEA3, SSEA4, TRA-1-60, TRA-1-81, IGF1 receptor, connexin 43, E-cadherin, Alkaline phosphatase, REX1, CRIPTO, CD24, CD90, CD29, CD9 and CD49f.

### Claim 16 (depends on 12)

The method of claim 12, wherein the biological activity is anticancer activity and step b) comprises detecting a reduction in colony initiating cells.

### Claim 17 (depends on 12)

The method of claim 12, wherein the biological activity is anticancer activity and step b) comprises detecting an increase in cell differentiation, an increase in loss of pluripotency, a decrease in cell proliferation, a decrease in cell number, a decrease in DNA content, a decrease in cell growth, an increase in cytotoxicity, or an increase in apoptosis.

### Claim at position 14

-19. (canceled)

### Claim 20 (depends on 12)

The method of claim 12, further comprising comparing the effect of the compound on the one or more t-hPSCs determined in step b) to an effect of the compound on one or more normal stem cells (SCs).

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The method of claim 20, wherein the effect of the compound on one or more normal stem cells (SCs) is determined by
c) contacting one or more stem cells (SCs) with the compound;
d) detecting an effect of the compound on the one or more SCs, wherein the effect is indicative of the biological activity of the compound.

### Claim 23 (depends on 22)

The method of claim 22, further comprising identifying compounds that exhibit a different level of biological activity on the one or more t-hPSCs compared to the one or more SCs.

### Claim 24 (depends on 23)

The method of claim 23, wherein the SCs are normal human pluripotent stem cells or normal induced pluripotent stem cells.

### Claim 25 (depends on 12)

The method of claim 12, further comprising placing one or more t-hPSCs into a receptacle and culturing the cells in the receptacle to form a monolayer prior to contacting the cells with the compound.

### Claim at position 21

-27. (canceled)

### Claim 28 (depends on 25)

The method of claim 25, wherein a single t-hPSC is placed into the receptacle and the monolayer of t-hPSCs is a homogeneous clonal colony of the single t-hPSC.

### Claim at position 23

-49. (canceled)

### Claim 50 (depends on 1)

A cell culture comprising a plurality of transformed human pluripotent stem cells (t-hPSCs) of claim 1.

### Claim at position 25

-53. (canceled)

### Claim 54

A method of identifying transformed pluripotent stem cells or transformed induced pluripotent stem cells comprising identifying stem cells that maintain expression of SSEA-3 when deprived of bFGF.

### Claim 55 (depends on 54)

The method of claim 54 comprising:
a) culturing pluripotent stem cells with bFGF;
b) analyzing the cells for SSEA-3 to provide a first level of SSEA-3 expression;
c) depleting the cell culture of bFGF;
d) analyzing the cells for SSEA-3 to provide at least a second level of SSEA-3 expression;
e) identifying those cells that maintain expression of SSEA-3 upon depletion of bFGF by comparing the first and second levels of SSEA-3 expression.

### Claim 56

(canceled)

### Claim 57

A method of identifying transformed pluripotent stem cells comprising
a) inhibiting Oct4 expression in a population of pluripotent stem cells; and
b) identifying undifferentiated cells that maintain expression of SSEA3.

### Claim at position 30

-78. (canceled)

### Claim 79 (depends on 1)

A method of screening a compound for use as chemotherapeutic agent comprising:
a) contacting the compound with the transformed human pluripotent stem cells of claim 1; and
b) determining whether the compound inhibits Nanog activity by monitoring for the loss of self-renewal and apoptosis of the transformed human pluripotent stem cells.

### Claim at position 32

-85. (canceled)
